Symphogen's Convertible Note Round

Symphogen raised a round of funding on October 22, 2015.

Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market. The company has advanced the fr…

Articles about Symphogen's Convertible Note Round: